Analysis of the Effect of Diltiazem Combined with Alprostadil Injection in the Treatment of Heart Failure Patients with Preserved Ejection Fraction

LIU Xiaojian; XUE Fangfang

doi:10.16458/j.cnki.1007-0893.2025.07.008

Abstract：Objective To analyze the therapeutic effect of diltiazem combined with alprostadil injection in patients with heart failure with preserved ejection fraction(HFpEF).Methods A total of 90 patients with HFpEF who visited Mengzhou Minsheng Hospital from January 2022 to January 2024 were selected as the research subjects and divided into a control group(46 cases)and an observation group(44 cases)according to different treatment regimens.Patients in the control group were treated with alprostadil injection,while those in the observation group were treated with diltiazem combined with alprostadil injection.The clinical efficacy,cardiac function,6-minute walk test(6-MWT),plasma brain natriuretic peptide(BNP)level,serum inflammatory factor level and the occurrence of adverse reactions of the two groups of patients were compared.Results The total effective rate of treatment in the observation group(90.91%)was higher than that in the control group(73.91%),and the difference was statistically significant(P<0.05).After treatment,the left ventricular end-systolic diameter(LVESD),mitral peak velocity in late diastolic(A),and left ventricular end-diastolic diameter(LVEDD)of the observation group were all smaller than those of the control group,while the mitral peak velocity in early diastolic(E)and mitral peak velocity in early diastolic/mitral peak velocity in late diastolic(E/A)were greater than those of the control group.The differences were statistically significant(P<0.05);After treatment,the 6-MWT distance of patients in the observation group was longer than that in the control group,and the level of BNP was lower than that in the control group,with statistically significant differences(P<0.05).After treatment,the levels of serum C-reactive protein(CRP),macrophage migration inhibitory factor(MIF),and interleukin-6(IL-6)in the observation group were all lower than those in the control group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups of patients(P>0.05).Conclusion Diltiazem combined with alprostadil injection has a significant therapeutic effect on HFpEF.This combined treatment plan can not only improve the patient's cardiac function,but also inhibit the inflammatory response in their body,and will not increase the risk of adverse reactions.